Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ADENUIRC is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that ADENURIC provides a minor improvement in actual benefit (level IV) in the management of symptomatic chronic hyperuricaemia compared to the current therapeutic strategy based on allopurinol. |
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
UhjncZggAGPCdQ4E
